8-K: Xeris Biopharma Reports Strong Q2 2026 Results, Tightens Guidance

Xeris Biopharma announced robust second quarter 2026 financial results, featuring a 34% year-over-year increase in net product revenue driven by Recorlev, and tightened its full-year revenue guidance.

Summary

• Total revenue for the second quarter of 2026 was $92.1 million, a 29% increase year-over-year.
• Net product revenue grew 34% to $91.0 million, primarily due to increased demand for Recorlev.
• Recorlev net revenue surged 81% year-over-year to approximately $57 million.
• Gvoke net revenue saw a slight decrease of 4% to $22.5 million.
• Keveyis contributed $11.7 million in net revenue, a 2% increase.
• Gross margin improved to 86% from 82% in the prior year's second quarter.
• R&D expenses increased by 32% to $10.7 million, supporting XP-8121 development.
• SG&A expenses rose by 37% to $61.0 million, supporting commercial expansion.
• Net loss for the quarter was $31.1 million, impacted by a $31 million non-cash charge related to convertible notes exchange.
• Adjusted EBITDA improved by $6.7 million to $19.3 million compared to the prior year's second quarter.
• Full-year 2026 total revenue guidance has been tightened to $385 million to $390 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and improved gross margins, though the net loss widened due to a one-time charge. The tightening of full-year guidance and patent news are also favorable.

Positives

• Net product revenue increased by 34% year-over-year to $91.0 million in Q2 2026.
• Recorlev demonstrated strong commercial momentum with an 81% year-over-year revenue increase to $56.8 million.
• Gross margin improved to 86% in Q2 2026, up from 82% in Q2 2025, driven by favorable product mix.
• Adjusted EBITDA for Q2 2026 was $19.3 million, an improvement of $6.7 million year-over-year.
• Adjusted EBITDA for the first six months of 2026 was $34.4 million, an improvement of $17.5 million year-over-year.
• Received a Notice of Allowance from the USPTO for a new Keveyis patent, expected to extend IP protection through at least 2039.
• Tightened full-year 2026 total revenue guidance to $385 million to $390 million, indicating confidence in business trajectory.

Negatives

• Net loss for the second quarter of 2026 was $31.1 million, compared to a net loss of $1.9 million in the same period last year.
• The widened net loss was primarily due to a one-time, non-cash charge of approximately $31 million related to the fair value increase from 2028 Convertible Notes exchange agreements.
• Gvoke net product revenue decreased by 4% year-over-year to $22.5 million in Q2 2026.
• Royalty, contract and other revenue decreased by 71% to $1.1 million in Q2 2026.
• R&D expenses increased by 32% year-over-year in Q2 2026.
• SG&A expenses increased by 37% year-over-year in Q2 2026.

Risks

• The company's financial position and need for financing to fund product development programs or commercialization efforts.
• Whether its products will achieve and maintain market acceptance in a competitive business environment.
• Reliance on third-party suppliers, including single-source suppliers.
• Reliance on third parties to conduct clinical trials.
• The ability of its product candidates to compete successfully with existing and new drugs.
• The ability to protect its intellectual property and proprietary technology.
• Accuracy and completeness of assumptions and the ability to accurately estimate future financial results and market opportunities.
• General macroeconomic and geopolitical conditions, including economic downturns, political unrest, trade disputes, changes in U.S. governmental priorities, tariffs, export controls, and market volatility.

Future Outlook

Full-year 2026 total revenue guidance has been tightened to a range of $385 million to $390 million. Management expresses confidence in the team, portfolio, and business trajectory. The company anticipates increasing contributions from strategic investments in Recorlev in the second half of 2026. The XP-8121 Phase 3 clinical trial is expected to commence later in 2026.

Management Comments

• "The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlevs exceptional commercial momentum."
• "The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasingly meaningful as we move through the second half of 2026."
• "Gvoke delivered solid sequential improvement in line with our expectations, and Keveyis continued to provide a consistent, high-value contribution to our business."
• "Beyond our commercial execution, the second quarter also brought an important strategic milestone. We received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new Keveyis patent expected to extend intellectual property protection through at least 2039, reinforcing our long-term commitment to the primary periodic paralysis community."
• "With a strong first half behind us, we are tightening our full-year guidance to $385$390 million, reflecting our confidence in the team, the portfolio, and the trajectory of our business."

Industry Context

StockSavvy.ai notes that Xeris Biopharma's performance aligns with a trend of increasing demand for specialized biopharmaceutical products, particularly those addressing niche or chronic conditions. The strong growth of Recorlev highlights the potential for well-executed commercial strategies in specific therapeutic areas. The company's focus on intellectual property protection, as evidenced by the Keveyis patent, is a common and crucial strategy in the biopharma industry to secure long-term market exclusivity and value.

Comparison to Industry Standards

• The 34% year-over-year net product revenue growth in Q2 2026 is robust, especially for a biopharmaceutical company with commercial-stage products. Many companies in the sector experience more modest growth rates or are in earlier development stages.
• The improvement in gross margin to 86% is a positive indicator of efficient operations and favorable product mix, often a benchmark for profitability in the pharmaceutical industry.
• The significant increase in SG&A expenses (37%) is typical for companies investing heavily in commercial expansion and product launches, such as Xeris with Recorlev.
• The widening net loss, while concerning, is explained by a one-time non-cash charge, a factor that analysts often adjust for when evaluating underlying operational performance. Companies like Xeris often prioritize growth and market penetration over immediate profitability, especially in their commercialization phases.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved Adjusted EBITDA, and tightened positive guidance. Potential dilution concerns may arise if future capital raises are needed, though none are indicated currently. The patent extension for Keveyis provides long-term value.
• Employees: Continued investment in R&D and commercial teams may lead to job growth and opportunities, but also increased SG&A expenses.
• Customers (Patients): Continued access to therapies like Recorlev, Gvoke, and Keveyis, with potential for future treatments like XP-8121.
• Creditors: The exchange of convertible notes reduces outstanding debt, potentially improving the company's credit profile.

Next Steps

• Management will host a webinar on September 9, 2026, to review the Phase 3 development program for XP-8121.
• Senior management will participate in 1x1 meetings and a fireside chat at the H.C. Wainwright Global Healthcare Conference on September 14, 2026.
• Senior management will participate in 1x1 meetings at the Morgan Stanley Global Healthcare Conference on September 15, 2026.
• The company expects the XP-8121 Phase 3 clinical trial to commence later in 2026.
• Continued focus on commercial execution and driving patient demand for Recorlev, Gvoke, and Keveyis.

Key Dates

Recommendation

The company shows strong operational performance with significant revenue growth and improved profitability metrics (Adjusted EBITDA). However, the widening net loss, increased operating expenses, and the inherent risks in biopharmaceutical development and commercialization warrant a cautious approach. The tightening guidance is positive, but the company's reliance on specific products and ongoing pipeline development suggests a 'hold' rating until further clarity on long-term profitability and pipeline success is achieved.

Keywords

Xeris Biopharma, Recorlev, Gvoke, Keveyis, XP-8121, Endogenous Cushings Syndrome, Severe Hypoglycemia, Primary Periodic Paralysis